1. Home
  2. FLNT vs SCYX Comparison

FLNT vs SCYX Comparison

Compare FLNT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLNT
  • SCYX
  • Stock Information
  • Founded
  • FLNT 2010
  • SCYX 1999
  • Country
  • FLNT United States
  • SCYX United States
  • Employees
  • FLNT N/A
  • SCYX N/A
  • Industry
  • FLNT Advertising
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLNT Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • FLNT Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • FLNT 47.1M
  • SCYX 50.3M
  • IPO Year
  • FLNT N/A
  • SCYX 2014
  • Fundamental
  • Price
  • FLNT $2.89
  • SCYX $1.12
  • Analyst Decision
  • FLNT Hold
  • SCYX Buy
  • Analyst Count
  • FLNT 1
  • SCYX 1
  • Target Price
  • FLNT $4.00
  • SCYX N/A
  • AVG Volume (30 Days)
  • FLNT 23.5K
  • SCYX 316.4K
  • Earning Date
  • FLNT 02-27-2025
  • SCYX 11-06-2024
  • Dividend Yield
  • FLNT N/A
  • SCYX N/A
  • EPS Growth
  • FLNT N/A
  • SCYX N/A
  • EPS
  • FLNT N/A
  • SCYX N/A
  • Revenue
  • FLNT $261,976,999.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • FLNT N/A
  • SCYX N/A
  • Revenue Next Year
  • FLNT $6.23
  • SCYX $365.06
  • P/E Ratio
  • FLNT N/A
  • SCYX N/A
  • Revenue Growth
  • FLNT N/A
  • SCYX N/A
  • 52 Week Low
  • FLNT $2.31
  • SCYX $0.90
  • 52 Week High
  • FLNT $4.30
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • FLNT 56.94
  • SCYX 44.06
  • Support Level
  • FLNT $2.53
  • SCYX $1.12
  • Resistance Level
  • FLNT $2.91
  • SCYX $1.49
  • Average True Range (ATR)
  • FLNT 0.13
  • SCYX 0.10
  • MACD
  • FLNT 0.04
  • SCYX -0.00
  • Stochastic Oscillator
  • FLNT 86.02
  • SCYX 27.31

About FLNT Fluent Inc.

Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers they are seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: